2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3576 Use of rituximab to eliminate minimal residual disease (MRD) in patients with MRD+ complete remission with encorafenib plus binimetinib in phase 2 testing for BRAF V600 mutated relapsed/refractory hairy cell leukemia

Robert J Kreitman, MD, Constance Yuan, MD, PhD2, Hao-Wei Wang, MD, PhD3, Dana Delgado Colon, MD4, Evgeny Arons, PhD5, Hong Zhou, MS6, Mark Raffeld, MD7, Liqiang Xi, MD8, Eager Holly, RN9, Lacey James, CRNP10, Katherine R Calvo, MD, PhD11, Irina Maric, MD12, Yoonhee Choi, M.D.13
1 National Institute of Health, Bethesda, Maryland, United States
2 National Institute of Health, Bethesda, Maryland, United States
3 National Institute of Health, Bethesda, Maryland, United States
4 National Institute of Health, Bethesda, Maryland, United States
5 National Institute of Health, Bethesda, Maryland, United States
6 National Institute of Health, Bethesda, Maryland, United States
7 National Institute of Health, Bethesda, Maryland, United States
8 National Institute of Health, Bethesda, Maryland, United States
9 National Institute of Health, Bethesda, Maryland, United States
10 National Institute of Health, Bethesda, Maryland, United States
11 National Institute of Health, Bethesda, Maryland, United States
12 National Institute of Health, Bethesda, Maryland, United States
13 National Institute of Health, Bethesda, Maryland, United States

Background: Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disorder responsive to purine analogs cladribine or pentostatin; however, relapses are common. Vemurafenib targets the BRAF V600E mutation driving >90% of classic HCL, achieving minimal residual disease (MRD) positive CR rates of 35-42%. Vemurafenib-rituximab achieved 87% CRs and 57% MRD-free CRs.  In BRAF V600-mutated melanoma, dabrafenib-trametinib, targeting BRAF-MEK, respectively, was both more effective and less toxic than vemurafenib targeting only BRAF.  In a multicenter trial of 55 HCL patients, dabrafenib-trametinib achieved CR rate 65.5%, with 12.7% MRD-free by bone marrow aspirate (BMA) flow cytometry (FC). In a preliminary report, Encorafenib-binimetinib, also targeting BRAF-MEK, had a 93% CR rate, (26/28 patients), but only 12% of CRs were MRD-free by BMA FC. We now present results from the full study and of delayed rituximab to eliminate MRD in those patients with MRD+ CR.

Patients and Methods: Thirty-two patients with BRAF V600-mutated HCL received oral encorafenib 450 mg/day and binimetinib 45 mg twice daily on a phase 2 NIH trial, with dose reduction to as low as 75 and 15 mg/day, respectively, for toxicity. The primary endpoint was to rule out a low CR rate of 35% in favor of 55%. CR criteria were based on HCL consensus guidelines. MRD was detected by marrow IHC and FC of blood and BMA. The main secondary endpoint was to avoid the pyrexia reported for dabrafenib-trametinib, 58.2%.  Eligibility required prior purine analog and therapeutic need, for neutrophils <1/nL, hemoglobin <10 g/dL, platelets <100/nL, symptomatic splenomegaly, or HCL masses >2 cm in short axis. Each cycle was 28 days; restaging with marrow evaluation and imaging was performed before cycles 4, 7, yearly until 2.5 years, then every 2 years.

Results: Of 32 total patients, 31 (97%) achieved CR. Time to CR was 10-176 (median 13) weeks, and 24 (75%) of 32 patients achieved CR by the earliest restaging time point. At 5.2-69.2 (median 34.0) months of follow-up, only 5 (16%) of the 31 CRs progressed. MRD-negativity by IHC was documented in 28 (90.3%) of 31 CRs, but only 6 (19.4%) were MRD-free by all criteria including the most stringent, BMA FC. Patients with MRD+ CR lasting >1 year were allowed to continue encorafenib-binimetinib while receiving either rituximab 375 mg/m2 (n=9) or obinutuzumab 1 g (n=2) every 2 weeks for 8 doses. Of 11 patients receiving anti-CD20 antibody (Mab) during MRD+ CR thus far, 7 (64%) achieved MRD-free CR, stopped encorafenib-binimetinib, and have remained MRD-free up to 3 years without MRD-recurrence. Prior to CD20 Mab in the 11 patients with MRD+ CR, HCL involvement varied in the bone marrow core IHC from negative to 10% and in the BMA FC from 0.02 to 6.25% of lymphocytes, and from 0.04 to 40.5% of B-cells; pre-CD20 Mab bone marrow status did not correlate with ability of CD20 Mab to clear MRD. However, of 2 patients with nodal disease, neither cleared MRD with CD20 Mab. Common (>20%) adverse events (AEs) related to encorafenib included high lipase (71%) and amylase (42%) frequently grade 3–4 but with symptomatic grade 2 pancreatitis in only one patient, hair thinning (45%) and abnormal hair texture (26%), nausea (42%), fatigue (39%), loose stools (39%), myalgias (39%), abdominal pain (35%), arthralgias (32%), skin induration (32%), constipation (26%), muscle cramps (23%), high cholesterol (23%), and maculopapular rash (23%). AEs related to binimetinib included transient serous retinopathy (55%), (grade 1-2 and mostly asymptomatic), high creatine kinase (48%, mostly grade 3 but asymptomatic), blurred vision (26%), dry skin (26%), acneiform rash (23%), and fatigue (23%). Pyrexia (fever >38.5oC), occurred in only 1 (3.1%) of 32 patients vs 32 (58.2%) of 55 who received dabrafenib-trametinib (p<0.0001 by Fisher’s exact).

Conclusion: Encorafenib-binimetinib is highly effective in relapsed/refractory HCL and well tolerated. Dose reductions enabled chronic dosing. The CR rate of 97% is higher than that achieved with dabrafenib-trametinib (66%, p=0.0005), although this is partly related to the single-institution design and greater experience with toxicity management and dosing. The use of CD20 Mab for those with MRD+ CRs markedly increases the MRD-free CR rate and follow-up continues to determine how well this will prevent relapse.

 

Robert J Kreitman, MD: AstraZeneca - Research Funding; Abbvie - Research Funding; Teva - Research Funding; pfizer - Research Funding; Novartis - Research Funding; Genentech - Research Funding